Edition:
United Kingdom

Obseva SA (OBSV.OQ)

OBSV.OQ on NASDAQ Stock Exchange Global Select Market

13.39USD
20 Apr 2018
Change (% chg)

$0.37 (+2.84%)
Prev Close
$13.02
Open
$13.23
Day's High
$13.39
Day's Low
$12.97
Volume
3,717
Avg. Vol
9,561
52-wk High
$15.81
52-wk Low
$5.02

Chart for

About

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109, an oral gonadotropin-releasing hormone (GnRH) receptor... (more)

Overall

Beta: --
Market Cap(Mil.): $257.50
Shares Outstanding(Mil.): 29.63
Dividend: --
Yield (%): --

Financials

  OBSV.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -1.86 -- --
ROI: -66.09 1.58 14.38
ROE: -68.51 2.41 16.07

BRIEF-ObsEva Reports Q4 Loss Per Share $0.48

* OBSEVA REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

09 Mar 2018

BRIEF-Obseva Q4 Loss Per Share $0.48

* OBSEVA REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

09 Mar 2018

BRIEF-Obseva Reports Positive Topline Results From Implant2 Phase 3 Clinical Trial Of Nolasiban In IVF

* OBSEVA SA REPORTS POSITIVE TOPLINE RESULTS FROM IMPLANT2 PHASE 3 CLINICAL TRIAL OF NOLASIBAN IN IVF

26 Feb 2018

BRIEF-Obseva SA Files For Mixed Shelf Of Upto $200 Mln

* OBSEVA SA FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING Source text : http://bit.ly/2rZEClR Further company coverage:

01 Feb 2018

BRIEF-Obseva Initiates Phase 2A Clinical Trial Of Obe022 In Preterm Labor

* OBSEVA INITIATES PROLONG, THE PHASE 2A CLINICAL TRIAL OF OBE022 IN PRETERM LABOR

05 Dec 2017

BRIEF-ObsEva SA files for resale of up to 7.5 million common shares‍​

* ObsEva SA - files for resale of up to 7.5 million common shares‍​ of co by the selling shareholders - SEC filing Source text: (http://reut.rs/2yMfBxk) Further company coverage:

09 Nov 2017

Earnings vs. Estimates